Health AI Central
Share:
Peer-Reviewed Publication
Am J Surg Pathol2026;50(5):543-549.May 1, 2026Journal Article

Clinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast.

Yulin Haw1, Gregor Krings2, Wen-Yu Hsiao1, Haiying Zhan3, Yanjun Hou4, Gloria Zhang2, Huina Zhang5, Shi Wei6, Wei Yang1, Marick Laé7, Miriam D Post8, Yi Liu9, Eliah R Shamir10, Marilin Rosa11, Kalliopi Siziopikou12, Stuart Schnitt13, Yunn-Yi Chen14, Xiaoxian Li1,15
1Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA.
2Department of Pathology, Cleveland Clinic, Cleveland, OH.
3Department of Pathology, Yale University School of Medicine, New Haven, CT.
4Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC.
5Department of Pathology, University of Rochester Medical Center, Rochester, NY.
6Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.
7Department of Pathology, Centre Henri Becquerel, Rouen, France.
8Department of Pathology, University of Colorado, Aurora, CO.
9Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
10Department of Pathology, Genentech.
11NeoGenomics Laboratories, Inc., Fort Myers, FL.
12Department of Pathology, University of Arizona, Tucson, AZ.
13Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.
14Department of Pathology, University of California San Francisco, San Francisco, CA.
15Department of Pathology and Laboratory Medicine, East Carolina University, Greenville, NC.
PubMed DOI

Abstract

High-grade serous-like carcinoma (HG-SL-Ca) of the breast is a newly recognized entity. We present the largest series with 34 cases. Inclusion criteria were breast carcinoma with ≥70% areas showing discordant well-formed tubules and high nuclear grade. Twenty-four (70.6%) were triple negative; 5 (14.7%) were ER+/HER2-; 2 (5.9%) were ER+/HER2+; and 3 (8.8%) were ER-/HER2+. Axillary lymph node metas…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.